Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) improve the outcomes across solid tumours, although they can cause severe immune-related adverse events (irAEs). Due to this possibility of side effects, practical and low-cost predictors of severe irAEs are needed to guide patient monitoring and care.

Methods

We conducted a single-centre retrospective cohort study involving 593 patients who were treated with anti-PD-1/PD-L1 monotherapy or anti-PD-1/PD-L1 plus anti-CTLA-4 combination therapy from June 2016 to November 2024. The primary endpoint was the time to the first severe irAE (grade ≥ 3). Peripheral blood biomarkers were evaluated at baseline and immediately before the cycle 3. The cumulative incidence was estimated, and the associations were quantified using the Fine-Gray

SUBMITTER: Acar C 

PROVIDER: S-EPMC12817496 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature